Want to see TMDX full AI Analyst Report?
TMDX Stock Chart & Stats
$92.22
$1.28(1.77%)
At close: 4:00 PM EDT
$92.22
$1.28(1.77%)
Day’s Range― - ―
52-Week Range$60.11 - $156.00
Previous CloseN/A
Volume216.03K
Average Volume (3M)815.03K
Market Cap
$2.51B
Enterprise Value$3.10B
Total Cash (Recent Filing)$472.68M
Total Debt (Recent Filing)$867.72M
Price to Earnings (P/E)16.4
Beta1.07
Next Earnings
Nov 04, 2026EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.42
Shares Outstanding34,675,144
10 Day Avg. Volume908,637
30 Day Avg. Volume815,027
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)8.74
Price to Sales (P/S)6.83
P/FCF Ratio30.96
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue4.64
Enterprise Value/Gross Profit7.90
Enterprise Value/Ebitda23.80
Forecast
1Y Price Target
$97.44Price Target Upside5.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)1.47
Revenue Forecast (FY)$743.64M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthStrong revenue growth reflects expanding adoption of the OCS platform and rising logistics utilization rather than a single temporary event. Continued product and service expansion should support greater operating scale and reinforce TransMedics’ position in transplant infrastructure over the next several quarters.
Recurring Case-Based Revenue ModelThe combination of reusable OCS systems, recurring consumables, and procedure-linked logistics services creates a durable revenue model tied to clinical usage. As hospitals and transplant networks adopt the platform, higher case volumes can expand recurring revenue without relying solely on new device placements.
Strong Liquidity And Cash GenerationA substantial cash balance and positive operating cash flow provide funding for product development, logistics expansion, and international growth without immediate dependence on external capital. This financial capacity supports execution of the company’s long-term platform strategy while offering resilience during investment-heavy periods.
Bears Say
Rising LeverageThe increase in leverage reduces financial flexibility as TransMedics funds expansion and absorbs higher interest costs. If profitability remains under pressure, a larger debt burden could constrain capital allocation, raise financing sensitivity, and leave less room to respond to operational setbacks or slower adoption.
Margin Compression And Heavy InvestmentLower operating-margin expectations show that growth is currently requiring substantial investment in OCS Kidney, Gen 3.0, ENHANCE, and DENOVO. These initiatives may strengthen the platform over time, but sustained spending and dilution from new programs can limit near-term earnings conversion and cash efficiency.
Approval And Expansion Execution RiskFuture growth depends partly on regulatory approvals, commercialization timing, and successful international execution. Delays affecting ENHANCE Part B, DENOVO, or European reimbursement could postpone expected revenue, extend investment periods, and make the long-term growth roadmap more dependent on existing transplant volumes.
TransMedics Group News
TMDX FAQ
What was TransMedics Group Inc’s price range in the past 12 months?
TransMedics Group Inc lowest stock price was $60.10 and its highest was $156.00 in the past 12 months.
What is TransMedics Group Inc’s market cap?
TransMedics Group Inc’s market cap is $2.51B.
When is TransMedics Group Inc’s upcoming earnings report date?
TransMedics Group Inc’s upcoming earnings report date is Nov 04, 2026 which is in 12 days.
How were TransMedics Group Inc’s earnings last quarter?
TransMedics Group Inc released its earnings results on Aug 04, 2026. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.496 by -$0.056.
Is TransMedics Group Inc overvalued?
According to Wall Street analysts TransMedics Group Inc’s price is currently Undervalued.
Does TransMedics Group Inc pay dividends?
TransMedics Group Inc does not currently pay dividends.
What is TransMedics Group Inc’s EPS estimate?
TransMedics Group Inc’s EPS estimate is 0.3.
How many shares outstanding does TransMedics Group Inc have?
TransMedics Group Inc has 34,675,144 shares outstanding.
What happened to TransMedics Group Inc’s price movement after its last earnings report?
TransMedics Group Inc reported an EPS of $0.44 in its last earnings report, missing expectations of $0.496. Following the earnings report the stock price went down -5.276%.
Which hedge fund is a major shareholder of TransMedics Group Inc?
Currently, no hedge funds are holding shares in TMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransMedics Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$97.44 (5.67% Upside)
$97.44 (5.67% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 319.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.73%
12-Months-Change
Fundamentals
Return on Equity
32.97%
Trailing 12-Months
Asset Growth
64.44%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
TransMedics Group Inc
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
TMDX Company Deck
TMDX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and commercial picture: record revenue, strong product and service growth (notably liver and logistics), improved sequential gross margin, robust cash balance, and raised revenue guidance. At the same time, the company is investing heavily in strategic initiatives (OCS Kidney, Gen 3.0, ENHANCE, DENOVO, European logistics/PAD) which is elevating R&D and operating expenses, tempering near-term operating margin and introducing execution and timing risk (IDE approvals, PAD integration and international reimbursement). Overall, the fundamentals and long-term growth roadmap are strong, but near-term profitability will be impacted by deliberate, front-loaded investments and some timing uncertainties.View all TMDX earnings summariesTMDX Stock 12 Month Forecast
Average Price Target
$97.44
▲(5.67% Upside)
Technical Analysis
Ownership Overview
3.55% Insiders
42.62% Mutual Funds
2.84% Other Institutional Investors
23.45% Public Companies and Individual Investors